Homology Medicines Inc (NASDAQ:FIXX) Receives $33.00 Average PT from Analysts

Share on StockTwits

Homology Medicines Inc (NASDAQ:FIXX) has been given a consensus recommendation of “Buy” by the six analysts that are presently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $33.00.

Several equities analysts recently issued reports on FIXX shares. Zacks Investment Research raised Homology Medicines from a “sell” rating to a “hold” rating in a research report on Tuesday, July 16th. Robert W. Baird assumed coverage on Homology Medicines in a research report on Monday, September 9th. They issued an “outperform” rating and a $30.00 target price on the stock. Canaccord Genuity set a $37.00 price target on shares of Homology Medicines and gave the company a “buy” rating in a report on Friday, July 26th. Finally, HC Wainwright set a $36.00 price target on shares of Homology Medicines and gave the company a “buy” rating in a report on Tuesday, June 11th.

In other Homology Medicines news, CFO W Bradford Smith sold 6,000 shares of the company’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $19.00, for a total value of $114,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Albert Seymour sold 9,300 shares of the company’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $17.37, for a total transaction of $161,541.00. Following the completion of the sale, the insider now directly owns 200,350 shares in the company, valued at $3,480,079.50. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 92,566 shares of company stock worth $1,714,997. 33.40% of the stock is owned by corporate insiders.

Several hedge funds have recently bought and sold shares of FIXX. BNP Paribas Arbitrage SA purchased a new stake in shares of Homology Medicines during the 1st quarter worth about $99,000. Spark Investment Management LLC purchased a new stake in shares of Homology Medicines during the 1st quarter worth about $1,200,000. TD Asset Management Inc. raised its position in shares of Homology Medicines by 15.8% during the 1st quarter. TD Asset Management Inc. now owns 27,868 shares of the company’s stock worth $773,000 after purchasing an additional 3,800 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of Homology Medicines during the 1st quarter worth about $74,000. Finally, Marshall Wace North America L.P. acquired a new position in shares of Homology Medicines during the 1st quarter worth about $2,582,000. 68.09% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ FIXX opened at $20.40 on Tuesday. The stock’s fifty day moving average price is $18.29 and its 200 day moving average price is $21.36. Homology Medicines has a 1 year low of $14.19 and a 1 year high of $31.80. The company has a market cap of $947.91 million, a price-to-earnings ratio of -10.20 and a beta of 0.11.

Homology Medicines (NASDAQ:FIXX) last released its earnings results on Thursday, August 8th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.06). Homology Medicines had a negative net margin of 3,232.67% and a negative return on equity of 38.74%. The firm had revenue of $0.39 million during the quarter, compared to analyst estimates of $1.00 million. As a group, sell-side analysts predict that Homology Medicines will post -2.27 earnings per share for the current year.

Homology Medicines Company Profile

Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Featured Story: Why are trading ranges significant?

Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.